

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
NBG-110

In re Application of: Daniela Fattori et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/554,152	October 21, 2005	Unassigned	48388	Unassigned	Unassigned

Title: NK-2 ANTAGONIST BASIC LINEAR COMPOUNDS AND FORMULATIONS CONTAINING THEM

Address to:  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).

# TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

Under 37 CFR 1.97(b) or 1.97(c)

Docket No.

NBG-110

In Re Application of: Daniela Fattori et al.

Application No. 10/554,152	Filing Date October 21, 2005	Examiner Unassigned	Customer No. 48388	Group Art Unit Unassigned	Confirmation No. Unassigned
-------------------------------	---------------------------------	------------------------	-----------------------	------------------------------	--------------------------------

Title: NK-2 ANTAGONIST BASIC LINEAR COMPOUNDS AND FORMULATIONS CONTAINING THEM

## Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☐ The Director is hereby authorized to charge and credit Deposit Account No. \_\_\_\_\_ as described below.
- ☐ Charge the amount of \_\_\_\_\_
  - ☐ Credit any overpayment.
  - ☐ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

### Certificate of Transmission by Facsimile\*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

### Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

June 28, 2006

Signature of Person Mailing Correspondence

Mark D. Lorusso

Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.

Signature

Dated: June 28, 2006

Mark D. Lorusso  
Reg. No. 41,955  
LORUSSO & ASSOCIATES  
3 Pinecrest Terrace  
Portsmouth, NH 03801  
Tel.: 603-427-0070  
Fax: 603-427-5530  
Email: mlorusso@lloplaw.com

CC:



PATENT  
ATTORNEY'S DOCKET NO.: NBG-110


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Daniela Fattori et al.  
Serial No.: 10/554,152  
Filed: October 21, 2005  
For: NK-2 ANTAGONIST BASIC LINEAR COMPOUNDS  
AND FORMULATIONS CONTAINING THEM  
Examiner: Not Assigned  
Art Unit: Not Assigned

---

CERTIFICATE OF MAILING

*I hereby certify that the following correspondence is being deposited with the United States Postal service as first class mail in an envelope addressed to the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313—1450 on June 28, 2006.*

  
Mark D. Lorusso

---

Commissioner for Patents  
PO BOX 1450  
Alexandria, VA 22313-1450

**STATEMENT FILED PURSUANT TO THE DUTY OF  
DISCLOSURE UNDER 37 C.F.R. §§1.56, 1.97 AND 1.98**

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the applicants request consideration of this information disclosure statement.

**Compliance with 37 C.F.R. §1.97**

This information disclosure statement has been filed before the mailing of a first office action on the merits. No fee or certification is required.

### **Information Cited**

The applicants hereby make of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the relative importance of the references.

### **Remarks**

Pursuant to 37 C.F.R. § 1.98(a)(2)(i), copies of non-U.S. patent references are enclosed unless otherwise indicated on the attached form PTO-1449 (modified). It is respectfully requested that:

- The examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
- The enclosed form PTO-1449 be signed by the examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
- The citations for the information be printed on any patent which issues from this application.

By submitting this information disclosure statement, the applicants make no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this information disclosure statement, the applicants make no representation that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this information disclosure statement, the applicants make no representation that the information cited in the statement is, or is considered to be, in

fact, prior art as defined by 35 U.S.C. §102.

It is understood by applicants that the foregoing information will be considered and, to the extent deemed appropriate by the examiner, will be reflected in the examiner's communication.

Respectfully submitted,


A handwritten signature in black ink, appearing to read 'Mark D. Lorusso', with a stylized flourish at the end.

Mark D. Lorusso  
Reg. No. 41,955  
Lorusso & Associates  
15 Rye Street, Suite 312  
Portsmouth, NH 03801  
Tel: (603) 427-0070  
Attorneys for Applicants

Docket No.: NBG-110

Date: June 28, 2006

(Use several sheets if necessary)



**Application Number**  
**10/554,152**

**Filing Date**  
**October 21, 2005**

Group Art Unit	Unassigned
----------------	------------

## PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		D. Regoli, E. Escher, J. Mizrahi; "Substance P-Structure-Activity Studies and the Development of Antagonists" (Pharmacology 28: 301-320 (1984)).

DATE CONSIDERED

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.